Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of LEO 152020 in adult patients with cholinergic urticaria
2020-004961-38Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cholinergic Urticaria (CU) comparing LEO 152020 with Placebo (2 arms). Primary endpoint: Change from baseline in post-provocation Urticaria Activity Score (UASprovo). Started Jan 2021; status: completed.
02
Drugs
JW1601
03
Conditions
Cholinergic Urticaria (CU)
Beyond the preview
Go deeper on 2020-004961-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004961-38.